Unilife Corp (UNIS) Earns Daily News Impact Rating of 0.31
Media coverage about Unilife Corp (NASDAQ:UNIS) has trended positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Unilife Corp earned a media sentiment score of 0.31 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 45.0440551222957 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Unilife Corp (UNIS) traded up 0.0000% during trading on Wednesday, hitting $0.1591. Unilife Corp has a 12-month low of $0.09 and a 12-month high of $6.20. The stock’s 50-day moving average price is $1.28 and its 200 day moving average price is $2.05.
WARNING: “Unilife Corp (UNIS) Earns Daily News Impact Rating of 0.31” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/unilife-corp-unis-earns-daily-news-impact-rating-of-0-31/1496068.html.
About Unilife Corp
Unilife Corp is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Company has a portfolio of product platforms, including pre-filled syringes, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems, and other systems for the targeted delivery of injectable therapies.
Receive News & Ratings for Unilife Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unilife Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.